NCT07378306 2026-01-30
FACT-TN
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
8 trialsNCT07372079 2026-01-28
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07161791 2025-09-09
Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Harbin Medical University
Phase 1/2 Not yet recruiting
NCT07101614 2025-08-03
A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
Shengjing Hospital
Phase 2 Not yet recruiting
NCT07005557 2025-06-05
SENIOR
Fudan University
Phase 3 Not yet recruiting
NCT06691594 2025-02-20
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06438055 2024-05-31
Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results
Tianjin Medical University Cancer Institute and Hospital
Phase NA Not yet recruiting
NCT05862610 2023-07-24
The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting